RxDoctor Payments Data

Niranjan Siva, MD

Neurology · Paducah, KYNPI 1154330157

Payments from drug & device makers

$9,623in general payments, 2019–2025

Across 673 payments — averaging $14.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$927
  • Supernus Pharmaceuticals, Inc.$640
  • Pfizer$539
  • Biohaven Pharmaceutical Holding Company Ltd.$382
  • Biogen$366
  • plus $5K from 52 others

What the payments were for

  • Consulting fees$1502%
  • Speaking & faculty fees$571%
  • Food & beverage$8,69390%
  • Education$7238%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)202$2,201
AstraZeneca24$927
Supernus Pharmaceuticals, Inc.45$640
Pfizer51$539
Biohaven Pharmaceutical Holding Company Ltd.42$382
Biogen16$366
Avanir Pharmaceuticals, Inc.20$341
Novartis25$322
Amgen20$282
SK Life Science, Inc.16$254
Acadia Pharmaceuticals Inc14$233
Bristol Myers Squibb15$221
Sunovion Pharmaceuticals Inc.20$208
Teva Pharmaceuticals USA, Inc.15$206
Lundbeck LLC10$171
Lilly USA, LLC13$169
Neurocrine Biosciences, Inc.9$146
Axsome Therapeutics, Inc.4$139
Mallinckrodt Hospital Products Inc.7$120
Mallinckrodt Enterprises LLC6$108
EMD Serono, Inc.7$104
Jazz Pharmaceuticals Inc.6$98
Grifols USA, LLC5$95
Genentech USA, Inc.6$93
E.r. Squibb & Sons, L.L.C.7$84
Livanova USA, Inc.4$83
UCB, Inc.5$79
Irhythm Technologies, Inc.1$77
Sumitomo Pharma America, Inc.7$76
CSL Behring4$67
Kyowa Kirin, Inc.5$62
Biohaven Pharmaceuticals, Inc.4$61
Harmony Biosciences LLC3$59
Acorda Therapeutics, Inc3$57
Inspire Medical Systems, Inc.3$56
Avion Pharmaceuticals1$44
Amneal Pharmaceuticals LLC3$40
Medtronic2$33
Abbott2$30
Zyla Life Sciences, Inc.2$30
Neurelis, Inc.2$29
Eisai Inc.1$23
Upsher-smith Laboratories LLC1$23
Adamas Pharmaceuticals, Inc.1$20
Impel Pharmaceuticals Inc.1$20
Chiesi USA, Inc.1$20
Banner Life Sciences, LLC1$19
Tanabe Pharma America, Inc.1$19
Sanofi1$16
Akcea Therapeutics, Inc.1$16
Portola Pharmaceuticals, LLC1$16
GE HealthCare1$15
Sanofi-aventis U.S. LLC1$15
Catalyst Pharmaceuticals, Inc.1$14
MDD US Operations, LLC1$14
ANI Pharmaceuticals, Inc.1$13
Idorsia Pharmaceuticals US Inc1$13
Collegium Pharmaceutical, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,623 in reported general payments places this provider in the 65th percentile of 210 neurology providers in Kentucky.

See all neurology providers in Kentucky

Medicare billing

Part B allowed, 2024
$206,676
Medicare patients
441
Services billed
2,276

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FirdapseAmifampridine Phosphate13$763,683
HizentraImmun Glob G(Igg)/Pro/Iga 0-5039$541,246
QuliptaAtogepant79$83,644
Nurtec OdtRimegepant Sulfate40$70,234
UbrelvyUbrogepant60$64,775
Aimovig AutoinjectorErenumab-Aooe45$37,932
TopamaxTopiramate22$25,173
FingolimodFingolimod Hcl14$21,928
EliquisApixaban35$21,493
Emgality PenGalcanezumab-Gnlm20$13,906
Tiagabine Hcl15$13,303
XcopriCenobamate11$11,976
Fentanyl54$11,749
Lacosamide88$11,207
Oxcarbazepine134$9,802

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Catalyst Pharmaceuticals, Inc.Firdapse$14$763,68313 claims
CSL BehringHizentra$67$541,24639 claims
AbbVieQulipta, Ubrelvy$2,201$148,418139 claims
PfizerNurtec Odt, Eliquis$539$91,72775 claims
SK Life Science, Inc.Xcopri$254$11,97611 claims
Upsher-smith Laboratories LLCTopiramate$23$1,745106 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$40$1,67023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 210 neurology providers in Kentucky.

Other neurology in Paducah

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →